



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**Complete if Known**

Application Number	10/560,385-Conf. #3846
Filing Date	January 12, 2007
First Named Inventor	Michael G. Orchard
Art Unit	1614
Examiner Name	Not Yet Assigned

Sheet	1	of	3	Attorney Docket Number	A0345.0021
-------	---	----	---	------------------------	------------

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		BA EP-0 536 402	04-14-1993	Nippon Shinyaku Company		✓
		BB EP 0 698 012 (WO-94/26714)	11-24-1994	G.D. Searle & Co et al.		✓

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	GIULIO ALESSANDRI, ET AL., "Angiogenic and Angiostatic Microenvironment in Tumors," Anct Onco. (1997), 36(4), pp. 383-387	
	CB	ANTHONY LUCCI, ET AL., "Glucosylceramide: a Marker for Multiple-Drug Resistant Cancers," Anticancer Res. (1998), 18(1B), pp. 475-480	
	CC	PETER DE MAN, ET AL., "Bacterial adherence as a virulence factor in urinary tract infection," APMIS (1990), 98(12), pp. 1053-1060	
	CD	KM NICHOLSON, ET AL., "Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase," Br. J. Cancer (1999), 81(3), pp. 423-430	
	CE	GUNNAR C. HANSSON, ET AL., "A novel approach to the study of glycolipid receptors for viruses," FEBS Lett. (1984), 170(1), pp. 15-18	
	CF	VICTOR JIMENEZ-LUCHO, ET AL., "Cryptococcus neoformans, Candida albicans, and Other Fungi Bind Specifically to the Glycosphingolipid Lactosylceramide (Galβ1-4Glcβ1-1Cer), a Possible Adhesion Receptor for Yeasts," Infect. Immun. (1990), 58(7), pp. 2085-2090	
	CG	YAAKOV LAVIE, ET AL., "Agents that Reverse Multidrug Resistance, Tamoxifen, Verapamil, and Cyclosporin A, Block Glycosphingolipid Metabolism by Inhibiting Ceramide Glycosylation in Human Cancer Cells," J. Biol. Chem. (1997) 272(3), pp. 1682-1687	
	CH	YONG-YU LIU, ET AL., "Uncoupling Ceramide Glycosylation of Transfection of Glucosylceramide Synthase Antisense Reverses Adriamycin Resistance," J. Biol. Chem. (2000), 275(10), pp. 7138-7143	
	CI	RUIXIANG LI, ET AL., "Cellular Gangliosides Promote Growth Factor-induced Proliferation of Fibroblasts," J. Biol. Chem. (2000), 275(44), pp. 34213-34223	
	CJ	IVAN Z. ZADOR, ET AL., "A Role for Glycosphingolipid Accumulation in the Renal Hypertrophy of Streptozotocin-induced Diabetes Mellitus," Clin. Invest. (1993), 91(3), pp. 797-903	
	CK	AKIRA ABE, ET AL., "Reduction of globotriaosylceramide in Fabry disease mice by substrate	

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

3

<i>Complete if Known</i>	
Application Number	10/560,385-Conf. #3846
Filing Date	January 12, 2007
First Named Inventor	Michael G. Orchard
Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	A0345.0021

CL	deprivation," J. Clin. Invest. (2000), 105(11), pp. 1563-1571
CM	ROBERT MCKALLIP, ET AL., "Tumor Gangliosides Inhibit the Tumor-Specific Immune Response," J. Immuno. (1999), 163(7), pp. 3718-3726
CN	MAJLIS SVENSSON, ET AL., "Carbohydrate Receptor Depletion as an Antimicrobial Strategy for Prevention of Urinary Tract Infection," J. Infect. Dis. (2001), suppl. 70-73, p. 183
CO	SUBROTO CHATTERJEE, ET AL., "Role of lactosylceramide and MAP kinase in the proliferation of proximal tubular cells in human polycystic kidney disease," J. Lipid. Res. (1996), 37(6), pp. 1334-1344
CP	TIMOTHY COX, ET AL., "Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis," Lancet (2000), 355(9214), pp. 1481-1485
CQ	N.V. PROKAZOVA, ET AL., "Gangliosides and Atherosclerosis," Lipids (1994), 29(1), pp. 1-5
CR	KAZUKO HANNA, ET AL., "Analysis of Glycolipid-Dependent Cell Adhesion Based on Carbohydrate-Carbohydrate Interaction," Methods Enzymol. (2000), 312, pp. 447-458
CS	CLIFFORD A. LINGWOOD, ET AL., "Analysis of Interactions between Glycosphingolipids and Microbial Toxins," Methods Enzymol. (2000), 312, pp. 459-473
CT	ABDERRAHIM MERZAK, ET AL., "Gangliosides Modulate Proliferation, Migration, and Invasiveness of Human Brain Tumor Cells In Vitro," Mol. Chem. Neuropathol. (1995), 24(2-3), pp. 121-135
CU	KAI SIMONS ET AL., "Functional rafts in cell membranes," Nature (1997), 387(6633), pp. 569-572
CV	PRAVEEN TYLE, "Iontophoretic Devices for Drug Delivery," Pharmaceutical Research (1986), 3(6), p. 318
CW	LINDA A. GOODMAN, ET AL., "Ectopic dendrites occur only on cortical pyramidal cells containing elevated GM2 ganglioside in $\alpha$ -mannosidosis," Proc. Natl. Acad. Sci. USA (1991), 88(24), pp. 11330-11334
CX	CHII-SHIARING CHEN, ET AL., "Abnormal transport along the lysosomal pathway in Mucolipidosis, type IV disease," Proc. Natl. Acad. Sci. USA (1998), 95(11), pp. 6373-6378
CY	MYLVAGANAM JEYAKUMAR, ET AL., "Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin," Proc. Natl. Acad. Sci. USA (1999), 96(11), pp. 6388-6393
CZ	FRANCES M. PLATT, ET AL., "Prevention of Lysosomal Storage in Tay-Sachs Mice Treated with N-Butyldeoxynojirimycin," Science (1997), 276(5311), pp. 428-431
CA1	MILTON ALTER, "GM <sub>1</sub> , Ganglioside for Acute Ischemic Stroke," Alter, Ann. NY Acad. Sci. (1998), 845, pp. 391-401
CB1	LIN-P'ING CHOO-SMITH ET AL., "Acceleration of Amyloid Fibril Formation by Specific Binding of A $\beta$ -(1-40) Peptide to Ganglioside-containing Membrane Vesicles," Biol. Chem. (1997), 272, pp 22987-22990
CC1	FOWLER, P.A. ET AL., "Synthesis and activity towards yeast $\alpha$ -glucosidase of 1,5-dideoxy-1,5-imino-L-iditol (1-deoxy-L-idonojirimycin), Carbohydr. Res. (1993), 246, pp. 377-381
CD1	FRED H. GEISLER, "Clinical Trials of Pharmacotherapy for Spinal Cord Injury," NY Acad. Sci. (1998), 845, pp . 374-381
CE1	MEMON, R.A. ET AL., "Regulation of Glycosphingolipid Metabolism in Liver during the Acute Phase Response," J. Biol. Chem. (1999), 274(28), pp. 19707-19713
CF1	MEMON, R.A., ET AL., "Regulation of sphingolipid and glycosphingolipid metabolism in

Examiner Signature	Date Considered
--------------------	-----------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
				Application Number	10/560,385-Conf. #3846
				Filing Date	January 12, 2007
				First Named Inventor	Michael G. Orchard
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	A0345.0021

		extrahepatic tissues by endotoxin," J. Lipid. Res. (2001), 42(3), pp. 452-459	
	CG1	OVERKLEEFT, H.S. ET AL., "Generation of Specific Deoxynojirimycin-type Inhibitors of the Non-lysosomal Glucosylceramidase," J. Biol. Chem. (1998), 273, pp. 26522-26527	
	CH1	FRANCES M. PLATT ET AL., "N-Butyldeoxygalactonojirimycin Inhibits Glycolipid Biosynthesis but Does Not Affect N-Linked Oligosaccharide Processing," J. Biol. Chem. (1994), 269, pp. 27108-27114	
	CI1	RAO, V.S. ET AL., "Regioselective eliminations in reactions of carbohydrate derivatives with superoxide, or with borohydride in 2-propanol," Can. J. Chem. (1981), 59(2), pp. 333-338	
	CJ1	RYAN, J.L. ET AL., "Changes in Membrane Gangliosides: Differentiation of Human and Murine Monocytic Cells," Yale J. Biol. Med. (1985), 58(2), pp. 125-131	
	CK1	J.S. SCHNEIDER, "GM1 Ganglioside in the Treatment of Parkinson's Disease," Anatomy and Cell Biology, (1990), 845, pp. 363-373	
	CL1	KATSUHIKO YANAGISAWA ET AL., "GM1 ganglioside-bound amyloid $\beta$ -protein (A $\beta$ ): A possible form of preamyloid in Alzheimer's disease," Nat. Med. (1995), 1, pp. 1062-1066	
	CM1	HERBERT C. YOHE, ET AL., "Ganglioside alterations in stimulated murine macrophages," Biochim. Biophys. Acta (1985), 818(1), pp. 81-86	
	CN1	HERBERT C. YOHE, ET AL., "Ganglioside expression in Macrophages from Endotoxin Responder and Non-Responder Mice," Immunol. (1986), 137(12), pp. 3921-3927	
	CO1	HERBERT C. YOHE ET AL., "The Presence of Sialidase-Sensitive Sialosylgangliotetraosyl Ceramide (GM1b) in Stimulated Murine Macrophages," Immunol. (1991), 146(6), pp. 1900-1908	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------